Table 2.

Overall proportion (low and high estimates) of cases targeted by a quadrivalent or a nonavalent HPV vaccine

		Low estimate	High estimate
Invasive cervical cancers (EDITH I)	Quadrivalent	69.2 [64.4-73.9]	82.2 [78.5-85.8]
	Nonavalent	84.5 [81.0-87.8]	92.1 [89.5-94.3]
	Absolute additional Impact* (% of additional prevented cases)	15.3% (p < 0.001)	9.9% (p < 0.001)
	Relative additional Impact**	22.1%	12.0%
High-grade cervical neoplasias (EDITH II)	Quadrivalent	43.4 [36.9-50.0]	64.7 [59.6-69.9]
	Nonavalent	76.7 [72.2-81.0]	89.5 [86.4-92.3]
	Absolute additional Impact (% of additional prevented cases)	33.3% (p < 0.001)	24.7% (p < 0.001)
	Relative additional Impact	76.6%	38.2%
Low-grade squamous intraepithelial lesions (EDITH III)	Quadrivalent	13.6 [5.6-24.1]	33.5 [25.6-41.4]
	Nonavalent	25.9 [17.5-35.0]	56.2 [49.8-62.8]
	Absolute additional Impact (% of additional prevented cases)	12.3% (p < 0.001)	22.7% (p < 0.001)
	Relative additional Impact	90.7%	67.7%
External acuminata condylomata (EDITH IV)	Quadrivalent	63.1 [57.3-68.9]	88.2 [84.7-91.4]
	Nonavalent	68.6 [63.1-73.8]	90.3 [87.2-93.2]
	Absolute additional Impact (% of additional prevented cases)	5.4% (p = 0.095)	2.1% (p = 0.318)
	Relative additional Impact	8.6%	2.4%
Anal cancers (EDITH V)	Quadrivalent	70.5 [64.7-76.0]	84.7 [80.6-88.7]
	Nonavalent	80.9 [76.4-85.1]	93.2 [90.3-95.6]
	Absolute additional Impact (% of additional prevented cases)	10.4% (p = 0.001)	8.5% (p < 0.001)
	Relative additional Impact	14.7%	10.0%
Oropharyngeal carcinomas (EDITH VI)	Quadrivalent	41.4 [33.1-50.0]	42.4 [33.8-51.1]
	Nonavalent	41.4 [33.1-50.0]	43.9 [35.5-52.2]
	Absolute additional Impact (% of additional prevented cases)	0.0% (NC)	1.6% (p = 0.687)
	Relative additional Impact	0.0%	3.8%

*Absolute additional potential impact of the nonavalent vaccine.

**Relative additional potential impact of the nonavalent vaccine.

NC, not calculated.